Skip to contentB
Bio-Rad Laboratories, Inc.
B
BIOBio-Rad Laboratories, Inc. Q2 2013 · 10-Q
Revenue$525.30M$525.30M+2.9% vs Q2 2012 Net Income$34.60M$34.60M−28.4% vs Q2 2012 EPS Diluted$1.20$1.20−29.0% vs Q2 2012 Gross Profit$300,100,000+4.2% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bio-Rad Laboratories, Inc. · CIK 12208 · Engraved from SEC EDGAR
Operating Cash Flowderived$19,737,000−73.2% Free Cash Flowderived-$4,758,000N/M Margins · derivedGross margin57.1%+0.7 pt vs Q2 2012
Operating margin10.1%−4.3 pt vs Q2 2012
Net margin6.6%−2.9 pt vs Q2 2012
ended Jun 30, 2013 · filed Aug 8, 2013 · 39 d after period end